[BREAKING] AstraZeneca, Russia's Partner to Make COVID-19 "Super Vaccine"
Oxford University's AstraZeneca company has now announced to make future partnership with Russia's COVID-19 vaccine candidate, Sputnik V vaccine.
Oxford and Russia to make collaboration
UK Prime Minister Boris Johnson poses for a photograph with a vial of the AstraZeneca/Oxford University COVID-19 candidate vaccine, known as AZD1222, at Wockhardt's pharmaceutical manufacturing facility on November 30, 2020 in Wrexham, Wales. The UK government announced a deal in August with global pharmaceutical and biotechnology company Wockhardt, to increase capacity in a crucial part of the manufacturing process for Covid-19 vaccines. Britain has been Europe's worst-hit country during the pandemic, recording more than 57,000 deaths from some 1.6 million cases.
Since pandemic is still active in today's time, a lot of companies have now tried to make a difference and create their own version of COVID-19 vaccine.
In the United States, Pfizer pharmaceutical company leads the vaccine experiment, with now seeking FDA approval. In the United Kingdom region, Oxford's entry starts with AstraZeneca medicinal firm. Another candidate is from Russia's Sputnik V vaccine.
All these three are the current leading vaccine candidates, around the world. However, the latter vaccines may be doing something different soon.
On Friday, Dec. 11, Oxford announced to make collaboration with Russia's Sputnik V. By the end of the year, the two firms are planning to mix both vaccines into one, according to the head of Russia's RDIF sovereign wealth fund, Kirill Dmitriev.
Will this be a COVID-19 'Supervaccine'?
People getting tested at a drive-through covid test station on November 20, 2020 in Budapest, Hungary. This weekend Hungary will receive the first batch of Russian made Sputnik V COVID-19 vaccine for trial tests. While the country was largely spared by the first wave of Covid-19 in the spring, the infection rates have surged in this second wave. According to data from the European Center for Disease Prevention and Control (ECDC), the country came in third given its death rate per 100,000 inhabitants, behind the Czech Republic and Belgium
Though AstraZeneca has not yet claimed anything, a lot of people were surprised to see this possible collaboration in the soonest time.
The Oxford vaccine has an efficacy rate of 90 percent. While, the Sputnik V claims 92 percent effectivity at protecting people from coronavirus, according to its interim trial results.
RELATED ARTICLE: How Does Pfizer-BioNTech Vaccine work?
© MD News Daily.